SIREN : 424604767
BIOBANK is a French company founded 26 years ago, specialized in the sector Fabrication de produits pharmaceutiques de base. Based in LIEUSAINT (77127), this company of category GE shows in 2023 a revenue of 16.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 16 616 272 € | 15 037 834 € | 14 061 407 € | 11 451 565 € | 12 911 746 € | 10 424 771 € | 8 711 026 € |
| Net income | 2 706 996 € | 2 113 864 € | 1 803 677 € | 1 227 916 € | 1 116 806 € | 1 907 970 € | 1 894 591 € |
| EBITDA | 3 637 514 € | 2 970 235 € | 2 603 553 € | 1 874 495 € | 1 763 152 € | 2 407 675 € | 1 802 333 € |
| Net margin | 16.3% | 14.1% | 12.8% | 10.7% | 8.6% | 18.3% | 21.7% |
In 2023, BIOBANK achieves revenue of 16.6 M€. Over the period 2016-2023, the company shows strong growth with a CAGR (compound annual growth rate) of +9.7%. Vs 2022, growth of +10% (15.0 M€ -> 16.6 M€). After deducting consumption (833 k€), gross margin stands at 15.8 M€, i.e. a rate of 95%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 3.6 M€, representing 21.9% of revenue. Positive scissor effect: EBITDA margin improves by +2.1 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.7 M€, i.e. 16.3% of revenue. This profit can be retained or distributed to shareholders.
16 616 272 €
15 783 191 €
3 637 514 €
3 394 590 €
2 706 996 €
21.8%
The debt ratio (= Financial debt / Equity x 100) stands at 21%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 65%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.8 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 17.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
20.731%
65.459%
17.72%
0.756
36.2%
In 2023, the debt ratio of BIOBANK (20.73) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2023, the financial autonomy of BIOBANK (65.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2023, the repayment capacity of BIOBANK (0.76) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 353.20. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.0x. Danger: operating income does not cover interest charges, unsustainable situation.
353.199
0.01
In 2023, the liquidity ratio of BIOBANK (353.20) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2023, the interest coverage of BIOBANK (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 48 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 80 days. Excellent situation: suppliers finance 32 days of the operating cycle (retail model). Inventory turnover is 123 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 219 days of revenue, i.e. 10.1 M€ to permanently finance. Over 2016-2023, WCR increased by +134%, requiring additional financing.
10 104 687 €
48 j
80 j
123 j
219 j
Compare BIOBANK with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de produits pharmaceutiques de base
The revenue of BIOBANK in 2023 is 16.6 M€.
Yes, BIOBANK generated a net profit of 2.7 M€ in 2023.
The headquarters of BIOBANK is located in LIEUSAINT (77127), in the department Seine-et-Marne.
The tax return of BIOBANK is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIOBANK operates in the sector Fabrication de produits pharmaceutiques de base (NAF code 21.10Z). See the 'Sector positioning' section above to compare the company with its competitors.